Related Experiment Videos
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern
Robert Gray1, Judith Manola, Scott Saxman
1Eastern Cooperative Oncology Group, Harvard School of Public Health, Boston, Massachusetts, USA.
Abstract:
Given the increase in novel agents and difficulty with planning and completing many phase III studies, various phase II trial design options should be considered to more effectively guide phase III trial plans. The need for novel phase II trial designs has increased, given the number of novel molecular targeted therapies now available for testing, an abundance of cytostatic agents, and limited resources to conduct phase III studies for all interesting agents or combinations. This review will focus on options for phase II trial designs. We review randomized phase II designs with placebo control, randomized selection designs, and randomized discontinuation designs. As agents become available for testing in the clinic, the strengths and weaknesses of different phase II trial designs should be considered to optimize a trial development plan that guides phase III trial decisions more effectively.
Insights
Novel phase II trial designs are crucial for efficiently evaluating new cancer therapies. This review explores options like randomized placebo, selection, and discontinuation designs to optimize phase III planning.
Area of Science:
- Oncology
- Clinical Trial Design
- Drug Development
Background:
- Increasing number of novel molecular targeted therapies and cytostatic agents require efficient evaluation.
- Limited resources necessitate optimized strategies for conducting Phase III studies.
- Challenges exist in planning and completing numerous Phase III trials.
Purpose of the Study:
- To review and discuss various Phase II clinical trial design options.
- To guide the selection of appropriate Phase II designs for effective Phase III planning.
- To enhance the optimization of drug development pathways.
Main Methods:
- Review of existing literature on Phase II clinical trial designs.
- Focus on randomized Phase II designs including placebo control, selection, and discontinuation models.
- Analysis of the strengths and weaknesses of each design.
Main Results:
- Identified key Phase II designs: randomized with placebo, randomized selection, and randomized discontinuation.
- Highlighted the importance of considering design-specific strengths and weaknesses.
- Emphasized the role of Phase II designs in informing Phase III decisions.
Conclusions:
- Strategic selection of Phase II trial designs is essential for efficient drug development.
- Optimized Phase II designs can improve the guidance of Phase III trial planning.
- Consideration of different designs helps maximize resource allocation in clinical research.
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:28Preclinical Development: Overview